Abiopharma

ANTERIS TECHNOLOGIES GLOBAL CORP. (AVR)

Symbol	AVR
Name	ANTERIS TECHNOLOGIES GLOBAL CORP.
Sector	HEALTH CARE
Region	North America
Industry	Industrial Specialties
Address	860 BLUE GENTIAN ROAD,SUITE 340, EAGAN, Minnesota, 55121, United States
Telephone	651-493-0606
Fax	—
Email	—
Website	https://anteristech.com/home.html
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002011514
Description	Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Our lead product, the DurAVR® transcatheter heart valve ("THV") system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and depoloyed with our ComASUR® balloon-expahndable delivery system. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Additional info from NASDAQ: Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Our lead product, the DurAVR® transcatheter heart valve ("THV") system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and depoloyed with our ComASUR® balloon-expahndable delivery system. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

2026-09-08 11:01

(99% Neutral) ANTERIS TECHNOLOGIES GLOBAL CORP. (AVR) Announces New Board Appointment

2026-09-03 19:26

New Form SCHEDULE 13G/A - Anteris Technologies Global Corp. Filed: 2026-09-03 AccNo: 0001817646-26-000027 Size: 8 KB

2026-09-01 10:24

L1 Capital Pty Ltd 🔴 sold 6.7M shares (2 derivative) of Anteris Technologies Global Corp. (AVR) at $11.50 ($15.4M) Transaction Date: Aug 28, 2026 | Filing ID: 000026

2026-08-20 23:49

St Denis David 🟡 adjusted position in 45.1K shares (1 derivative) of Anteris Technologies Global Corp. (AVR) at $9.58 ($1.1M) Transaction Date: Aug 19, 2026 | Filing ID: 033942

2026-08-14 17:46

New Form SCHEDULE 13G/A - Anteris Technologies Global Corp. Filed: 2026-08-14 AccNo: 0001104659-26-097295 Size: 11 KB

2026-08-12 10:13

L1 Capital Pty Ltd 🔴 sold 7.3M shares (2 derivative) of Anteris Technologies Global Corp. (AVR) at $11.50 ($21.1M) Transaction Date: Aug 10, 2026 | Filing ID: 000020

2026-08-12 09:01

New Form 424B3 - Anteris Technologies Global Corp. Filed: 2026-08-12 AccNo: 0001140361-26-032391 Size: 1 MB

2026-08-10 11:24

L1 Capital Pty Ltd 🔴 sold 6.9M shares (2 derivative) of Anteris Technologies Global Corp. (AVR) at $11.50 ($16.7M) Transaction Date: Aug 06, 2026 | Filing ID: 000019

2026-07-31 12:38

(99% Neutral) ANTERIS TECHNOLOGIES GLOBAL CORP. (AVR) Files Form 8-K

2026-07-31 10:25

L1 Capital Pty Ltd 🔴 sold 6.1M shares (1 derivative) of Anteris Technologies Global Corp. (AVR) at $8.20 ($5.8M) Transaction Date: Jul 29, 2026 | Filing ID: 000015

No clinical trials found for this company.

No clinical products found for this company.